Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
06/2009
06/18/2009DE202009003780U1 Kräuterzusammensetzung Herbal composition
06/18/2009CA2709301A1 Modulators of cystic fibrosis transmembrane conductance regulator
06/18/2009CA2709203A1 Hedgehog pathway antagonists and therapeutic applications thereof
06/18/2009CA2708706A1 Cannabinoid receptor modulators
06/18/2009CA2708303A1 Cyclic urea inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1
06/18/2009CA2707679A1 Agent for treating ulcer
06/18/2009CA2707313A1 Novel heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
06/18/2009CA2707105A1 Inhibitors of stearoyl-coa desaturase
06/18/2009CA2707047A1 Carboxamide, sulfonamide and amine compounds for metabolic disorders
06/17/2009EP2071036A2 Methods for identifying RNA-binding compounds
06/17/2009EP2070944A1 Specific binding agents of human angiopoietin-2
06/17/2009EP2070939A1 Modulators of pharmacological agents
06/17/2009EP2070930A1 Polycycloalkylpurines as adenosine receptor antagonists
06/17/2009EP2070927A1 Fused heterocyclic derivative
06/17/2009EP2070926A1 13,13a-DIHYDROBERBERINE DERIVATIVES, THEIR PHARMACEUTICAL COMPOSITION AND USE
06/17/2009EP2070921A1 Indolylmaleimide derivatives as protein kinase c inhibitors
06/17/2009EP2070919A1 Spiroquinone compound and pharmaceutical composition
06/17/2009EP2070911A2 Stabilized 1Alpha-Hydroxy vitamin D
06/17/2009EP2070540A1 Drug composition for treating 2 type diabetes and its chronicity neopathy
06/17/2009EP2070539A1 8-[3-amino-piperidin-1-yl]-xanthins, their production and utilisation as medicine
06/17/2009EP2069383A2 Synthetic bile acid composition, method, and preparation
06/17/2009EP2069374A1 Crystalline solvates and complexes of (is) -1, 5-anhydro-l-c- (3- ( (phenyl) methyl) phenyl) -d-glucitol derivatives with amino acids as sglt2 inhibitors for the treatment of diabetes
06/17/2009EP2069331A1 1h-indol-6-yl-piperazin-1-yl-methanone-derivatives for use as h3 receptor modulators
06/17/2009EP2069319A1 Cyclic sulfones useful as mitochondrial sodium-calcium exchangers
06/17/2009EP2069297A1 2-methylene-(20r,25s)-19,27-dinor-(22e)-vitamin d analogs
06/17/2009EP2069296A2 2-methylene-(20s,25s)-19,27-dinor-(22e)-vitamin d analogs
06/17/2009EP2068910A2 Use of exendins and exendin agonists and glp-1 receptor agonists for altering lipoprotein particle size and subclass composition
06/17/2009EP2068902A2 Tea-derived compostiions and methods of using same for cardiovascular health
06/17/2009EP2068891A2 Composition comprising crustacean gastrolith components, calcium carbonate and its use
06/17/2009EP2068885A1 Vitamin d compositions and method of administration to a human being
06/17/2009EP2068884A2 Hydroxycholesterols and its prodrugs for the treatment of insulin resistance and disorders associated therewith
06/17/2009EP2068870A2 Thiophene compounds
06/17/2009EP2068861A2 Compositions comprising omega-3 fatty acids, and their use in treating peripheral artery disease and intermittent claudication
06/17/2009EP2068859A1 New pharmaceutical compositions comprising a thyroid hormon and their therapeutic use
06/17/2009EP2068858A1 New pharmaceutical compositions comprising diiodothyronine and their therapeutic use
06/17/2009EP2068853A2 Treatment of insulin resistance or diseases associated with insulin resistance with bicyclo[3.2.1]octans such as steviol and isosteviol
06/17/2009EP2068819A2 Dendrimer compositions
06/17/2009EP2068663A1 Satiety inducing products and a method of their production
06/17/2009EP1735320B1 Compounds and methods for treating dyslipidemia
06/17/2009EP1648933B1 Long lasting insulin derivatives and methods thereof
06/17/2009EP1566384B1 Novel azole derivatives
06/17/2009EP1485381B1 Azolylaminoazine as inhibitors of protein kinases
06/17/2009EP1435957B1 Inhibitors of gsk-3 and crystal structures of gsk-3beta protein and protein complexes
06/17/2009EP1390378B1 Pharmaceutically active uridine esters
06/17/2009EP1357115B1 Alkanoic acid derivatives, process for their production and use thereof
06/17/2009EP1337518B1 Piperazinylpyrazines compounds as antagonists of serotonin 5-ht2 receptor
06/17/2009CN100500853C Fusion protein for secretion of protein of interest in supernatant of bacterial culture
06/17/2009CN100500669C Salviolic acid berberine compound salt, its preparation method and application
06/17/2009CN100500187C Chinese herbal medicine composition for dissolving stasis, lowering blood fat and blood pressure
06/17/2009CN100500164C Process for preparing bee glue water solution and use
06/17/2009CN100500148C A buffered, liquid nicotine composition for pulmonary administration
06/17/2009CN100500147C New formulations and use thereof
06/16/2009US7547802 Compounds for the treatment of metabolic disorders
06/16/2009US7547730 Preventive and/or therapeutic treatment of hyperlipidemia or non-insulin dependent diabetes mellitus which comprises dministering orally a polyprenyl compound 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid (NIK-333); antidiabetic and -lipemic agents
06/16/2009US7547728 (N-(4-nitro-3-trifluoromethyl)phenyl)-(2S)-3-(4- (acetylamino) phenoxy)-2-hydroxy-2-methylpropanamide) derivatives
06/16/2009US7547723 Comprehensive pharmacologic therapy for treatment of a dysfunction
06/16/2009US7547705 Ethyl-1'-[(2S)-2-hydroxy-2-phenylethyl]-6'-oxo-8'-(pyridin-4-yl)-1',3',4',6'-tetrahydro-1H-spiro[piperidine-4,2'-pyrimido[1,2-a]pyrimidine]-1-carbox; glycogen synthase kinase-3 beta, amyloid precursor protein, tau protein hyperphosphorylation inhibitor; neurodegenerative disease, type II diabetes
06/16/2009US7547698 Bicyclic heterocyclic derivatives and their use as inhibitors of stearoyl-coadesaturase (SCD)
06/16/2009US7547697 Alkyl-pyridazine derivatives as 11b-HSD1 inhibitors
06/16/2009US7547693 Piperidine derivative
06/16/2009US7547532 Three-dimensional structure of prostaglandin D synthase and utilization thereof
06/16/2009CA2451474C Triamide-substituted indoles, benzofuranes and benzothiophenes as inhibitors of microsomal triglyceride transfer protein (mtp) and/or apolipoprotein b (apo b) secretion
06/16/2009CA2396180C Stable aqueous deoxyfructosazine solution
06/16/2009CA2388314C Imidazole derivatives as phosphodiesterase vii inhibitors
06/16/2009CA2385995C Quinuclidine compound and medicament comprising the compound as active ingredient
06/16/2009CA2334877C Dietary supplement derived from fermented milks for the prevention of osteoporosis
06/11/2009WO2009073300A1 [1h- pyrazolo [3, 4-b] pyridine-4-yl] -phenyle or -pyridin-2-yle derivatives as protein kinase c-theta
06/11/2009WO2009073186A1 Oxysterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and wnt signaling
06/11/2009WO2009073138A2 Treatment of metabolic syndrome with novel amides
06/11/2009WO2009072886A1 Protein-dense micellar casein-based liquid enteral nutritional composition
06/11/2009WO2009072885A1 High energy liquid enteral nutritional composition
06/11/2009WO2009072884A1 Liquid enteral nutritional composition with a low specific protein volume
06/11/2009WO2009072869A1 High energy liquid enteral nutritional composition
06/11/2009WO2009072625A1 Amplification method for hematopoietic stem cells with heterocyclic compound
06/11/2009WO2009072581A1 Lactam compound or salt thereof, and ppar activator
06/11/2009WO2009071850A2 Nanoparticles of therapeutic agents having low water solubility
06/11/2009WO2009071689A2 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases
06/11/2009WO2009071687A1 Amidomethyl-substituted oxindole derivatives and the use thereof for the treatment of vasopressin-dependent illnesses
06/11/2009WO2009071658A1 Piperazines as anti-obesity agents
06/11/2009WO2009071601A1 Boropeptide inhibitors of enteropeptidase and their uses in treatment of obesity, overweight and/or diseases associated with an abnormal fat metabolism
06/11/2009WO2009071509A1 1,2-disubstituted-4-benzylamino-pyrrolidine derivatives as cetp inhibitors useful for the treatment of diseases such as hyperli pidemia or arteriosclerosis
06/11/2009WO2009071483A1 1- (indaz0l-5-yl) -ureas as diacylglycerol acyltransferase inhibitors
06/11/2009WO2009071099A1 Elevation of the plasma hdl-cholesterol level
06/11/2009WO2009071086A2 Probiotic bacteria and regulation of fat storage
06/11/2009WO2009070974A1 Therapeutic composition containing amlodipine nicotinate and statins
06/11/2009WO2009070873A1 Substituted 2-naphthoic acids as antagonists of gpr105 activity
06/11/2009WO2009054682A3 Prodrug of atrovastatin by cholesterol's synthesis inhibitors
06/11/2009WO2009033818A3 Use of a peptide as a therapeutic agent
06/11/2009WO2009033787A3 Use of a peptide as a therapeutic agent
06/11/2009WO2009033786A3 Use of a peptide as a therapeutic agent
06/11/2009WO2009033759A3 Use of a peptide as a therapeutic agent
06/11/2009WO2009033740A3 Use of a peptide as a therapeutic agent
06/11/2009WO2009033722A3 Use of a octreotide as a therapeutic agent
06/11/2009WO2009033719A3 Use of a deslorelin and mastoparan as a therapeutic agent
06/11/2009WO2008147373A3 Methods and compositions for reducing body weight using an estrogen fatty ester in an oil
06/11/2009WO2008046758A3 Imidazolone and imidazolidinone derivatives as 11b-hsd1 inhibitors for diabetes
06/11/2009WO2008019147A3 Use of exendins, exendin agonists and glp-1 receptor agonists for altering the concentration of fibrinogen
06/11/2009US20090149831 Polymeric Microspheres for Treatment of Obesity
06/11/2009US20090149539 Pet food compositions and methods
06/11/2009US20090149537 Use of Bile Acid or Bile Salt Fatty Acid Conjugates
1 ... 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 ... 1298